Long‐term results of a prospective, single‐arm evaluation of everolimus‐eluting bioresorbable vascular scaffolds in infrapopliteal arteries

2020 ◽  
Author(s):  
Ramon L. Varcoe ◽  
Theo P. Menting ◽  
Shannon D. Thomas ◽  
Andrew F. Lennox
Keyword(s):  
Long Term Results ◽  
Vascular Scaffolds ◽  
Bioresorbable Vascular Scaffolds ◽  
Infrapopliteal Arteries

scholarly journals Bioresorbable vascular scaffolds in the routine clinical practice: long-term results

2020 ◽  
Author(s):  
Ricardo Mori-Junco ◽  
Luis Furuya-Kanamori ◽  
Pablo Salinas ◽  
Luis Nombela Franco ◽  
Pilar Jiménez Quevedo ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Routine Clinical Practice ◽  
Long Term Results ◽  
Vascular Scaffolds ◽  
Bioresorbable Vascular Scaffolds

scholarly journals Bioabsorbable vascular scaffolds in routine practice: long-term results

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
R M Mori ◽  
I N G Nunez
Keyword(s):  
Protective Factor ◽  
Randomized Clinical Trials ◽  
Real Life ◽  
Long Term Results ◽  
Routine Practice ◽  
Target Vessel ◽  
Intracoronary Imaging ◽  
Vascular Scaffolds

Abstract Background Recent publications suggest that bioabsorbable vascular scaffolds (BVS) carry an excess of thrombotic complications. Our goal was to describe the results in real life and in the long term, in a series of patients who received a BVS which is currently off the market. Methods Two hundred and thirteen consecutive patients who received at least 1 BVS between May 2012 and December 2016 were analyzed. The primary objective was the incidence of the compound event “target vessel failure” that included infarction or target vessel revascularization and cardiac death. Results Seventy-five percent of patients were men with a mean age of 61.4 years. They had a high prevalence of dyslipidemia (62.44%) and smoking (65.26%). The most common cause of admission was myocardial infarction without ST elevation (53.52%). A total of 233 coronary lesions were treated, with an average of 1.3±0.3 lesions per patient. The implant was successful in 99.5% of cases. Predilatation was performed in 89.3% and post dilation in 33.5% of cases. The use of intracoronary imaging (Optical Coherence Tomography OCT and/or Intravascular ultrasonography IVUS) to optimize the BVS implant was performed in 86 patients (40.38%). With a mean follow-up of 42.5 months, the incidence of target vessel failure was 6.57% during the first 24 months and 7.98% at the end of the follow-up. Regarding the device, this included 6 cases (2.81%) of thrombosis (definitive, probable or possible) and 10 cases (4.69%) of restenosis. Patients with a history of diabetes mellitus (HR 1.72 95% CI 1.01–2.95 P=0,05) and/or chronic oral anticoagulation (HR 5.71 95% CI 1.12–28.94 P=0.04) had a higher risk of target vessel failure. The use of intracoronary imaging (OCT and/or IVUS) during the BVS implantation had a considerable trend toward significance as a protective factor (HR 0.32 95% CI 0.11–1.03 P=0.06). Conclusions In this series of patients; in real life conditions, the incidence of target vessel failure was comparable to that previously described in randomized clinical trials. The events were more frequent during the first 2 years of follow-up, in the presence of greater cardiovascular comorbidity and in the absence of intracoronary imaging during the implantation. FUNDunding Acknowledgement Type of funding sources: Other. Main funding source(s): European Society of Cardiology KM curve for target vessel failure (TVF) Predictor analysis for TVF

scholarly journals Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Alberto Polimeni ◽  
Remzi Anadol ◽  
Thomas Münzel ◽  
Ciro Indolfi ◽  
Salvatore De Rosa ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Meta Analysis ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Vascular Scaffolds ◽  
Bioresorbable Vascular Scaffolds ◽  
Artery Disease

The DESolve® novolimus bioresorbable scaffold

2021 ◽  
Author(s):  
Pierluigi Demola ◽  
Francesco Meucci ◽  
Miroslava Stolcova ◽  
Carlo Di Mario ◽  
Alessio Mattesini
Keyword(s):  
Polymer Scaffold ◽  
Bioresorbable Scaffold ◽  
Incomplete Stent Apposition ◽  
Radial Strength ◽  
Vessel Patency ◽  
Vascular Scaffolds ◽  
Bioresorbable Vascular Scaffolds ◽  
Controversial Topic ◽  
Long Term Impact

A longtime aspiration of interventional cardiologists remains to improve the long-term impact of stent permanence in coronaries to restore original vessel patency and physiological endothelium response. Bioresorbable vascular scaffolds were considered revolutionary in coronary devices, but several trials were disappointing; thus, the challenge in this field remains. DESolve is a novolimus-eluting poly-L lactide-based polymer scaffold that dissolves through a bio-reabsorption mechanism, vanishing completely in 2 years. Its ability to supply the necessary radial strength to support the vessel for the critical early months after delivery is an important feature showing a unique self-correction property, which reduces incomplete stent apposition. Overexpansion has a good, safe margin with DESolve. This review aims to provide an overview of this controversial topic.

Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients

2017 ◽  
Vol 234 ◽  
pp. 58-63 ◽  
Author(s):  
Kristian Hellenkamp ◽  
Alexander Becker ◽  
Yannick D. Gabriel ◽  
Gerd Hasenfuß ◽  
Mark Hünlich ◽  
...  
Keyword(s):  
Term Outcome ◽  
Long Term Outcome ◽  
Vascular Scaffolds ◽  
Bioresorbable Vascular Scaffolds

scholarly journals Long-term clinical outcomes for bifurcation treatment using a provisional T-stenting and double proximal optimization technique with Absorb bioresorbable scaffolds

2017 ◽  
Vol 21 (1) ◽  
pp. 50
Author(s):  
R. D. Ivanchenko ◽  
A. V. Birukov ◽  
K. A. Smirnov
Keyword(s):  
Coronary Artery ◽  
Conflict Of Interest ◽  
Optimization Technique ◽  
Drug Eluting Stent ◽  
Long Term Follow Up ◽  
Vascular Scaffolds ◽  
Bioresorbable Vascular Scaffolds ◽  
Bifurcation Lesions

<p><strong>Aim.</strong> The article presents long-term outcomes of treatment of coronary artery bifurcation lesions by using bioresorbable vascular scaffolds and provisional T-stenting combined with double proximal optimization. <br /><strong>Methods.</strong> 14 patients aged 44-80 years (mean age 61±6 years) including 8 (57.14 %) males underwent endovascular treatment of coronary artery bifurcation lesions by using Absorb bioresorbable vascular scaffolds (BVS). Clinical/instrumental analysis was carried out after 23.7±4.12 months. Angiographic examination was performed in 12 cases (85.71 %). 7 patients (50 %) underwent optical coherent tomography. <br /><strong>Results.</strong> 11 patients (78.57) were free of angina during long-term follow-up. 1 patient (7.14 %) developed BVS thrombosis and received a drug-eluting stent. A neointimal layer of the main branch increased during long-term follow-up to 29.23±7.82%, that of the lateral branch – up to 19.2±7.48%. Optical coherence tomography (OCT) shows that all strata are fully covered with neointima, the number of strata with malappositions is minimal and the loss of the main branch diameter (16.9±4.9%) is insignificant. <br /><strong>Conclusion.</strong> The use of Absorb bioresorbable vascular scaffolds implanted by means of provisional T-stenting combined with double proximal optimization when treating coronary artery bifurcation lesions is a safe and efficient procedure.</p><p>Received 2 February 2017. Accepted 10 March 2017.</p><p><strong>Financing:</strong> The study did not have sponsorship.<br /><strong>Conflict of interest:</strong> The authors declare no conflict of interest.</p>

Sign in / Sign up

Export Citation Format

Share Document